Zavain is enthralled by the power of data and its counterpart, intelligence. He invests in companies that are using machine learning and AI to augment or replace physical-world functions including biology, language, manufacturing and analysis.
Zavain has led Lux’s investments in Primer, a stealth machine intelligence startup; Clarifai, which combines machine intelligence and image recognition; Capella, which is developing novel medicines based on computational insight applied to genomic data; Recursion which uses automation and deep learning to develop drugs for rare diseases; and Tempo Automation, which applies software and automation to electronics manufacturing.
Previously Zavain was an investor at Eric Schmidt’s Innovation Endeavors. There he sourced and led the firm’s investments in early-stage technology companies including Zymergen and BlockStream. Zavain drafted the firm’s theses in Genetics, Synthetic Biology and the Blockchain.
Before VC, Zavain was a founder and computer scientist. At Discovery Engine (acquired by Twitter), he engineered machine learning and AI systems across a proprietary distributed computing framework to build web scale-ranking algorithms. Zavain was also a co-founder of Fountainhop, one of the first hyper-local social networks.
Zavain holds a bachelor's degree in symbolic systems and a master's degree in computer science from Stanford where he was a researcher in Stanford’s AI Lab. He is currently a Lecturer at Stanford and has taught quarter-long seminars in Cryptocurrencies, Artificial Intelligence and Philosophy and Venture Capital.
What is Zavain Dar's net worth?
The estimated net worth of Zavain Dar is at least $325,090.92 as of December 14th, 2023. Mr. Dar owns 53,823 shares of Recursion Pharmaceuticals stock worth more than $325,091 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Dar may own. Learn More about Zavain Dar's net worth.
How do I contact Zavain Dar?
Has Zavain Dar been buying or selling shares of Recursion Pharmaceuticals?
Zavain Dar has not been actively trading shares of Recursion Pharmaceuticals within the last three months. Most recently, Zavain Dar sold 20,141 shares of the business's stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $9.00, for a transaction totalling $181,269.00. Following the completion of the sale, the director now directly owns 53,823 shares of the company's stock, valued at $484,407. Learn More on Zavain Dar's trading history.
Who are Recursion Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Recursion Pharmaceuticals?
In the last year, insiders at the sold shares 61 times. They sold a total of 1,151,301 shares worth more than $10,096,309.56. The most recent insider tranaction occured on November, 13th when CFO Michael Secora sold 15,000 shares worth more than $114,900.00. Insiders at Recursion Pharmaceuticals own 15.8% of the company.
Learn More about insider trades at Recursion Pharmaceuticals. Information on this page was last updated on 11/13/2024.
